Literature DB >> 18951720

Matriderm versus Integra: a comparative experimental study.

Joerg Schneider1, Thomas Biedermann, Daniel Widmer, Irene Montano, Martin Meuli, Ernst Reichmann, Clemens Schiestl.   

Abstract

AIM: To compare engraftment rates and vascularisation in a rat model using either Integra Artificial Skin or Matriderm.
METHODS: Matriderm and the dermal part of Integra were compared in a two-step procedure including matrix implantation and subsequent epidermal grafting. Neonatal rat epidermis was used as coverage to test for rapid and complete take.
RESULTS: Efficiency and quality of vascularisation expressed by take rate of epidermis, and thickness of resulting neodermis, were identical for both matrices.
CONCLUSION: This first comparison of Matriderm with Integra in a rat model revealed no major differences in engraftment rates or vascularisation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951720     DOI: 10.1016/j.burns.2008.07.018

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  29 in total

1.  Skingineering I: engineering porcine dermo-epidermal skin analogues for autologous transplantation in a large animal model.

Authors:  Erik Braziulis; Thomas Biedermann; Fabienne Hartmann-Fritsch; Clemens Schiestl; Luca Pontiggia; Sophie Böttcher-Haberzeth; Ernst Reichmann; Martin Meuli
Journal:  Pediatr Surg Int       Date:  2011-03       Impact factor: 1.827

2.  Tissue engineering of skin: human tonsil-derived mesenchymal cells can function as dermal fibroblasts.

Authors:  Sophie Böttcher-Haberzeth; Thomas Biedermann; Agnieszka S Klar; Luca Pontiggia; Jürgen Rac; David Nadal; Clemens Schiestl; Ernst Reichmann; Martin Meuli
Journal:  Pediatr Surg Int       Date:  2014-02       Impact factor: 1.827

3.  Premiere use of Integra™ artificial skin to close an extensive fetal skin defect during open in utero repair of myelomeningocele.

Authors:  Martin Meuli; Claudia Meuli-Simmen; Alan W Flake; Roland Zimmermann; Nicole Ochsenbein; Ianina Scheer; Luca Mazzone; Ueli Moehrlen
Journal:  Pediatr Surg Int       Date:  2013-09-22       Impact factor: 1.827

4.  Use of a collagen-elastin matrix for hard to treat soft tissue defects.

Authors:  Uwe Wollina; Antje Meseg; Andreas Weber
Journal:  Int Wound J       Date:  2011-03-30       Impact factor: 3.315

Review 5.  [Keloid and hypertrophic scar treatment modalities. An update].

Authors:  L K Branski; H O Rennekampff; P M Vogt
Journal:  Chirurg       Date:  2012-09       Impact factor: 0.955

6.  The use of Matriderm and autologous skin grafting in the treatment of diabetic ulcers: a case report.

Authors:  Valerio Cervelli; Lucilla Lucarini; Caterina Cerretani; Diana Spallone; Ludovico Palla; Lorenzo Brinci; Barbara De Angelis
Journal:  Int Wound J       Date:  2010-06-08       Impact factor: 3.315

7.  The use of skin substitutes in the treatment of the hand and upper extremity.

Authors:  John T Capo; Kyle P Kokko; Marco Rizzo; Julie E Adams; Ben Shamian; Brenon Abernathie; Eitan Melamed
Journal:  Hand (N Y)       Date:  2014-06

8.  The influence of stromal cells on the pigmentation of tissue-engineered dermo-epidermal skin grafts.

Authors:  Thomas Biedermann; Sophie Böttcher-Haberzeth; Agnieszka S Klar; Daniel S Widmer; Luca Pontiggia; Andreas D Weber; Daniel M Weber; Clemens Schiestl; Martin Meuli; Ernst Reichmann
Journal:  Tissue Eng Part A       Date:  2015-01-07       Impact factor: 3.845

9.  Tissue-engineered dermo-epidermal skin analogs exhibit de novo formation of a near natural neurovascular link 10 weeks after transplantation.

Authors:  Thomas Biedermann; Agnieszka S Klar; Sophie Böttcher-Haberzeth; Clemens Schiestl; Ernst Reichmann; Martin Meuli
Journal:  Pediatr Surg Int       Date:  2014-02       Impact factor: 1.827

10.  Analysis of blood and lymph vascularization patterns in tissue-engineered human dermo-epidermal skin analogs of different pigmentation.

Authors:  Agnieszka S Klar; Sophie Böttcher-Haberzeth; Thomas Biedermann; Clemens Schiestl; Ernst Reichmann; Martin Meuli
Journal:  Pediatr Surg Int       Date:  2014-02       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.